Clinical Trial Update: Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A neoadjuvant Nimotuzumab trial in resectable esophageal squamous cell carcinoma was withdrawn (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Peking University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: WITHDRAWN